Four billion! Yuheng Pharmaceuticals to buy turnover of 1.44 million yuan company

On July 10, Yu heng Pharmaceuticals issued a public announcement on the progress of its major asset restructuring, which showed that Yuheng expects to acquire no less than 35% of Tymco Bio for no less than 4 billion yuan in order to gain control of Tyme Bio. The final price is based on audit and evaluation and shall be determined by the two parties in consultation separately.
notable, according to the announcement, Tyme Bio's annual revenue is only 1.44 million yuan.4 billion yuan, the purchase turnover of 1.44 million yuan of the company
in the main financial data of Tianma Bio, as of December 31, 2017, Tianma Bio's total assets of 1.49 billion yuan, net assets of 1.46 billion yuan, by 2017, Tianma Bio realized operating income of 1.4449 million yuan.
why would Yu Heng buy a company with revenues of only 1.44 million yuan at a price of 4 billion yuan?
has been working on insulin and insulin-like drugs, and has not been officially put into operation, according to the company's announcement. Operating income in 2017 was mainly due to service charges, sample sales revenue, etc. As a result, the amount of operating income is small.
is perhaps a "low-key treasure" in itself for Yu Heng.
well known, the industrialization of insulin has very high technical barriers. For many years, China's insulin market has been dominated by foreign pharmaceutical companies.
although the diabetes industry technical barriers are high, but I have a huge market space. The International Diabetes Alliance (IDF) released the 7th edition of the diabetes map in early 2016. Its data show that the number of diabetics in China has reached 109.6 million, accounting for about 26.4% of the world's diabetics.
According to public data, China's diabetes public medical institutions market sales volume expanded from 27.8 billion in 2013 to 41 billion in 2016, a compound growth rate of 13.8%, overlay retail pharmacy terminal sales, the overall market size of diabetes in 2016 nearly 50 billion yuan.
perhaps in the layout of the reputation, the Tyme creature is the best grasper of the layout of the diabetes market.
first, Tyme Bio's technology comes from Israel's BTG, which is known as the "big four" in the field of insulin, with Noor and Nord, Lilly and Sanofi. BTG mastered the world's core second- and third-generation insulin development technology, and in 2010 developed the world's latest insulin production technology, and then transferred the latest research and development results to Tyme Bio. On this basis, Tymma bio to the introduction of second-generation insulin technology digestion and absorption, with Israel, the United States and other foreign biotechnology companies to cooperate.
Second, Tianmai established a recombinant human insulin production platform with independent intellectual property rights, creating a second- and third-generation insulin 7 products, 27 product regulations of the full range of insulin needles and oral capsule product chain, becoming the third industry-wide biopharmaceutical enterprises after Tonghua Dongbao, Ganli.
, long-term injections can be painful for patients in order to change the way insulin is given. Thyme Bio has teamed up with Oramed, an Israeli pharmaceutical company that specializes in the development of oral protein dosing technology, to build a platform for oral protein dosing technology. At present, oral insulin in the completion of Phase II clinical trials, and actively promote the use of transfer technology and domestic raw material preparations in the United States Phase III multi-center clinical research.
industry experts have commented that if this oral insulin is successful, it will solve the worldwide problem of oral insulin dosing, bringing about a revolutionary change in the use of drugs by diabetics.Tianmai, is only one step in the field of reputational balance layout of chronic diseases
In fact, the more important reason is that the strategic layout of the field of chronic diseases, from the past reputation of the operation of the action can be seen.
28, 2016, Yu Heng and Jiangsu Jingdong Bangnong co-financed the establishment of Yuheng Jingdong Health Investment Management Co., Ltd. The announcement shows that Yudong Health mainly layout oral chronic disease drug market.
February 22, 2016, Yu Heng paid $25 million through its wholly-owned subsidiary, Yu Heng (Hong Kong), to subscribe for Proteus Digital Health, Inc., an H-wheel preferred stock issued to obtain priority negotiation rights for the commercialization of smart pills in China in the future.
On December 8, 2015, Yu heng and the first third pharmaceutical (Shanghai) Co., Ltd. signed the "Aotan Promotion and Distribution Cooperation Framework Agreement", enjoying the exclusive promotion and distribution rights of Amethatan ester tablets (commodity name: Aotan) in the designated area within the scope of Chinese mainland, Autan as the main variety in the field of treatment of hypertension, enriched the product reserves in the field of cardiovascular and cerebrovascular.
September 24, 2015, Yu Heng signed the Recombined Human Insulin Product Supply and Distribution Agreement with Bioton S.A. of Poland and its Singapore subsidiary SciGen Limited, which covers products already on Chinese mainland market. One of Bioton S.A's main products is recombining human insulin, increasing the stock of products in the diabetes field.
And yuheng proposed to obtain a biological control of Tymma, perhaps is optimistic about its product layout in the field of diabetes, so as to enrich the category of insulin products in the field of credit medicine, combined with its own channel resources, promotional resources and sales experience, to enhance its competitiveness in the field of diabetes and chronic diseases. (Seber Blue)